Skip to main content
Year archive

Xlife Sciences AG — 2025 filings

All 40 regulatory filings released by Xlife Sciences AG (XLS) in 2025, sourced directly from the official regulator.

40 Filings
2025 Period
2025 filings (40)
Filing Released Lang
Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG
Regulatory Filings
2025-12-31 English
Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG
Regulatory Filings
2025-12-31 English
Update zu den laufenden Transaktionen mit dem Pharmaunternehmen Grupo Landsteiner und dem NASDAQ-Listing der VERAXA Biotech AG
Regulatory Filings
2025-12-31 German
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
Regulatory Filings
2025-12-23 English
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
Regulatory Filings
2025-12-23 English
Xlife Sciences AG beschliesst Wechsel an das Hauptsegment der SIX Swiss Exchange zur Stärkung der Marktpräsenz
Regulatory Filings
2025-12-23 German
Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio
Regulatory Filings
2025-12-12 English
Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio
Regulatory Filings
2025-12-12 English
Preisgekrönter Leber-PET-Tracer unterstreicht die Stärke unseres Innovationsportfolios
Regulatory Filings
2025-12-12 German
Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform
M&A Activity
2025-12-08 English
Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform
M&A Activity
2025-12-08 English
Xlife Sciences AG verkündet Exit von 12 Projektgesellschaften an Grupo Landsteiner und den Aufbau einer skalierbaren transkontinentalen Life-Sciences-Plattform
M&A Activity
2025-12-08 German
Xlife Sciences AG Delivers Breakthrough in Early Alzheimers Detection, Unlocking Major Market Opportunity
Regulatory Filings
2025-12-01 English
Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
Regulatory Filings
2025-12-01 English
Xlife Sciences AG erzielt Durchbruch bei der Früherkennung von Alzheimer und erschließt bedeutendes Marktpotenzial
Regulatory Filings
2025-12-01 German
Xlife Sciences AG Provides Update on VERAXA Biotech AGs NASDAQ Listing Process Following U.S. Government Shutdown
Regulatory Filings
2025-11-28 English
Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown
M&A Activity
2025-11-28 English
Xlife Sciences AG gibt ein Update zum Stand des NASDAQ-Listing-Prozesses der VERAXA Biotech AG nach US-Regierungsstillstand bekannt
Regulatory Filings
2025-11-28 German
Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
Report Publication Announcement
2025-10-16 English
Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
Report Publication Announcement
2025-10-16 English
Xlife Sciences AG veröffentlicht ESG-Bericht 2024: Nachhaltige Wertschöpfung als strategischer Kern
Environmental & Social Information
2025-10-16 German
Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AGs NASDAQ Listing and Internationalization
Report Publication Announcement
2025-09-23 English
Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization
Earnings Release H1 2025
2025-09-23 English
Xlife Sciences AG Halbjahresbericht 2025: Fokus auf NASDAQ-Listing der VERAXA Biotech AG und Internationalisierung
Earnings Release H1 2025
2025-09-23 German
Xlife Sciences AGs Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
M&A Activity
2025-07-17 English
Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
M&A Activity
2025-07-17 English
Portfoliounternehmen der Xlife Sciences AG, VERAXA Biotech AG, erreicht wichtigen Meilenstein auf dem Weg zum NASDAQ Listing mit Einreichung des Emissionsprospekts (F-4 Filing)
M&A Activity
2025-07-17 German
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
AGM Information
2025-06-24 English
Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025
AGM Information
2025-06-24 English
Xlife Sciences AG: Erfolgreiche Generalversammlung und Wachstumsaussichten in 2025
AGM Information
2025-06-24 German
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
Regulatory Filings
2025-06-16 English
Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia
Regulatory Filings
2025-06-16 English
Strategische Zusammenarbeit zwischen Xlife Sciences AG, Huraypositive Corp. und OncoMASTER Inc. zur Förderung von digitaler Medizin und Präzisionsonkologie in Asien
M&A Activity
2025-06-16 German
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures Access to Global Capital Markets
M&A Activity
2025-06-13 English
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets
M&A Activity
2025-06-13 English
Strategische Allianz zwischen Xlife Sciences AG, JIPYONG LLC und JIPYONG IP soll koreanischen Life-Sciences-Unternehmen den Zugang zu globalen Kapitalmärkten ermöglichen
Regulatory Filings
2025-06-13 German
Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy
Environmental & Social Information
2025-05-07 English
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
Report Publication Announcement
2025-05-05 English
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence
Report Publication Announcement FY 2024
2025-04-25 English
From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to merge with Voyager Acquisition Corp. listed on NASDAQ
M&A Activity
2025-04-23 English